NANJING, China, May 21,
2024 /PRNewswire/ -- The 10th European Stroke Organization
Congress (ESOC), held in Basel,
Switzerland from May 15 to 17,
2024, showcased six studies on Sanbexin® (Edaravone and
Dexborneol Concentrated Solution for Injection) and a new dosage
form of sublingual tablets under development. These presentations
brought new medical evidence on the mechanism of action and
clinical application of Sanbexin® in treating stroke.
Highlights
Sanbexin®, the only Class 1 innovative drug approved worldwide
since 2015, has been shown to reduce brain cell damage and
dysfunction caused by ischemia and hypoxia in stroke patients. Its
significance lies in its ability to combat the devastating effects
of stroke, which is the second most common fatal disease globally
and the first most common in China.
The high recurrence rate, disability rate, and mortality rate
associated with stroke place a heavy burden on society. In
China, the incidence rate of
ischemic stroke is the highest worldwide. Sanbexin® has been
approved to address these challenges, offering new hope for
patients and their families.
Furthermore, the New Drug Application (NDA) for Sublingual
Tablets of Sanbexin® has been accepted by the National Medical
Products Administration (NMPA) on June 28,
2023. This development is expected to fill a critical gap in
first-time and out-of-hospital drug delivery after stroke onset,
increasing accessibility to the entire treatment course from
hospital-based care to out-of-hospital care for patients.
Photo -
https://mma.prnewswire.com/media/2417738/Extraction_Study.jpg
Photo - https://mma.prnewswire.com/media/2417864/2.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/simcere-phar-maceuticals-presented-six-studies-on-sanbexin-at-esoc-2024-302151158.html